Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.29)
# 1,189
Out of 4,412 analysts
57
Total ratings
53.85%
Success rate
0.81%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $110 | $80.91 | +35.95% | 8 | Apr 25, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $925 | $883.20 | +4.73% | 3 | Apr 17, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $4.23 | +53.66% | 3 | Mar 15, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Overweight | $12 → $10 | $4.91 | +103.67% | 3 | Feb 23, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Neutral | $165 → $150 | $143.31 | +4.67% | 15 | Feb 23, 2024 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $440 | $397.48 | +10.70% | 15 | Feb 20, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $78 | $65.42 | +19.23% | 4 | Feb 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $55 | $44.85 | +22.63% | 5 | Nov 15, 2023 | |
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $72 | $53.91 | +33.56% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Apr 25, 2024
Reiterates: Overweight
Price Target: $110
Current: $80.91
Upside: +35.95%
Regeneron Pharmaceuticals
Apr 17, 2024
Reiterates: Neutral
Price Target: $925
Current: $883.20
Upside: +4.73%
MannKind
Mar 15, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $4.23
Upside: +53.66%
Aurinia Pharmaceuticals
Feb 23, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $4.91
Upside: +103.67%
Alnylam Pharmaceuticals
Feb 23, 2024
Maintains: Neutral
Price Target: $165 → $150
Current: $143.31
Upside: +4.67%
Vertex Pharmaceuticals
Feb 20, 2024
Reiterates: Overweight
Price Target: $440
Current: $397.48
Upside: +10.70%
Gilead Sciences
Feb 7, 2024
Maintains: Neutral
Price Target: $80 → $78
Current: $65.42
Upside: +19.23%
Bristol-Myers Squibb Company
Nov 15, 2023
Downgrades: Neutral
Price Target: $68 → $55
Current: $44.85
Upside: +22.63%
CRISPR Therapeutics AG
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $53.91
Upside: +33.56%